CD34 and lymphoma: In a study by Lefrère et al. 19 in France, where the efficacy of biosimilar Zarzio was compared to Neupogen for chemo-mobilization in a population consisting of both multiple myeloma and lymphoma patients, it was found that the median CD34+ cells collected was comparable between both arms (p = 0.26), with a slightly higher number of cells collected from Zarzio (5.5 × 106) as compared to Neupogen (4.49 × 106).